Piramal Enterprises acquires Mallinckrodt's Pharma Products for $203 million

By: Pharma Tips | Views: 997 | Date: 31-Jan-2017

Ajay Piramal led Piramal Enterprises has acquired a portfolio of anti-spasticity and pain management drugs from US based drug maker Mallinckrodt in an all cash deal. The $171 million (Rs 1160 crore) deal also includes an additional $32 million payable, depending on the financial performance of the acquired assets over the next three years.

Piramal Enterprises acquires Mallinckrodt's pharma products for $203 million

Ajay Piramal led Piramal Enterprises has acquired a portfolio of anti-spasticity and pain management drugs from US based drug maker Mallinckrodt in an all cash deal. The $171 million (Rs 1160 crore) deal also includes an additional $32 million payable, depending on the financial performance of the acquired assets over the next three years.

The acquired products include Gablofen (brand baclofen) for treatment of severe spasticity and  two pain management drugs under development. Currently, marketed in the US and approved for launch in eight European Countries, these products had generated revenues of $44.6 million, in the one year period ending September 2016.

"This would be our seventh pharma acquisition in the last two years, taking our investment for inorganic growth to Rs. 3,000 crores across our pharmaceutical businesses", said Ajay Piramal, chairman, Piramal Enterprises.

"These acquisitions add branded products that are in attractive niches with barriers to entry and limited competition. Along with our Inhalation Anesthesia products, we are building portfolio to offer our customers and a substantially more diversified revenue base," said Peter DeYoung, CEO of Piramal Critical Care.

After the sale of its formulation business to Abbott in 2010 for a record Rs 18,500 crore, Piramal's pharma businesses are restricted to contract manufacturing, critical care, healthcare information management and consumer products. Piramal Enterprises re-deployed majority of rest of the money got from Abbott into financial services. Ajay Piramal also runs a large real estate business.

The listed Piramal Enterprises had revenues of Rs 3,558 crore in 2015-16, with a compounded annual growth rate (CAGR) of 17 per cent in the last six years.

Previous Page Next Page

People Searching On This Page:

Related Pages


BSC/ MSC/ B.Pharma/ M.Pharma Jobs as Quality Assurance Jobs in Sun Pharma

BSC/ MSC/ B.Pharma/ M.Pharma Jobs as Quality Assurance Jobs in Sun Pharma

Jobs | Quality Assurance
Date:
21-Dec-2016  Views: 45501

Sun Pharma ranks amongst India's largest pharma companies We’ve built a reputation for speciality therapy leadership and faster- than-industry growth ...
Lupin acquires US based Gavis Pharma for $880 million

Lupin acquires US based Gavis Pharma for $880 million

News | Pharma Companies
Date:
31-Jul-2015  Views: 3032

Pharma major Lupin Limited has acquired a US-based privately held research-oriented generic company Gavis Pharmaceuticals LLC and Novel Laboratories I ...
Sun Pharma acquires US-based injectable company Pharmalucence

Sun Pharma acquires US-based injectable company Pharmalucence

News | Pharma Companies
Date:
28-Jul-2014  Views: 3762

Pharma major Sun Pharmaceutical, on Wednesday, said that it has acquired Pharmalucence Inc, a US based injectable company for an undisclosed sum. ...
B.Pharma/M.Pharma/M.Sc Required for Production, QA, QC Jobs in USV

B.Pharma/M.Pharma/M.Sc Required for Production, QA, QC Jobs in USV

Jobs
Date:
11-May-2014  Views: 7181

We are 2000 cr health care company with operations in India, US & EU, with leadership in diabetes and cardiovascular segments. We provide a supportive ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

30  + 1 =     
Comments

Google : 13 times | Yahoo : 7 times |